全文获取类型
收费全文 | 1134篇 |
免费 | 121篇 |
出版年
2021年 | 12篇 |
2016年 | 13篇 |
2015年 | 18篇 |
2014年 | 40篇 |
2013年 | 37篇 |
2012年 | 51篇 |
2011年 | 56篇 |
2010年 | 40篇 |
2009年 | 31篇 |
2008年 | 47篇 |
2007年 | 55篇 |
2006年 | 35篇 |
2005年 | 38篇 |
2004年 | 44篇 |
2003年 | 24篇 |
2002年 | 28篇 |
2001年 | 27篇 |
2000年 | 24篇 |
1999年 | 23篇 |
1998年 | 14篇 |
1997年 | 14篇 |
1996年 | 9篇 |
1995年 | 16篇 |
1994年 | 16篇 |
1993年 | 16篇 |
1992年 | 19篇 |
1991年 | 22篇 |
1990年 | 25篇 |
1989年 | 28篇 |
1988年 | 19篇 |
1987年 | 22篇 |
1986年 | 18篇 |
1985年 | 20篇 |
1984年 | 30篇 |
1983年 | 19篇 |
1982年 | 20篇 |
1981年 | 19篇 |
1980年 | 9篇 |
1979年 | 16篇 |
1978年 | 24篇 |
1977年 | 20篇 |
1976年 | 9篇 |
1975年 | 12篇 |
1974年 | 14篇 |
1972年 | 12篇 |
1971年 | 11篇 |
1969年 | 10篇 |
1968年 | 9篇 |
1966年 | 9篇 |
1965年 | 11篇 |
排序方式: 共有1255条查询结果,搜索用时 78 毫秒
51.
52.
53.
54.
55.
A model lipid membrane consisting of a monolayer of dioleoyl phosphatidylcholine (DOPC) adsorbed onto a Hg electrode has been used to study the interaction between the lipid and different formulations of Amphotericin B (AmB) [Fungizone® (FZ), Heated Fungizone (HFZ), and Abelcet®]. The lipid organizational order was measured by electrochemical methods [capacitance and metal ion (Tl+) reduction], characterizing the change in lipid order due to interaction with the drug. The mean size and number density of pores formed in the monolayer were estimated by fitting the reduction current transients to a random array of microelectrode model. This method was shown sensitive for investigation of the interaction of drugs with the DOPC monolayer. Abelcet was found to have a smaller disruptive effect on lipid order than FZ and HFZ. The formulations used to solubilize the AmB were also studied. Sodium deoxycholate used as a solubilizer in FZ displayed significant influence on lipid order similar to that observed for Abelcet. The lipid complex, used in Abelcet, did not significantly perturb the DOPC monolayer order. The lipid complex used in Abelcet may have an annealing or healing effect that buffers the disruption possible due to AmB. 相似文献
56.
Maren Ziegler Shannon K. FitzPatrick Ingo Burghardt Katie L. Liberatore A. Joshua Leffler Cristina Takacs-Vesbach Ursula Shepherd 《Coral reefs (Online)》2014,33(4):1085-1099
In this study, we examined two non-scleractinian taxa, the rare nudibranch Phyllodesmium lizardensis and Bayerxenia sp., the octocoral on which the nudibranch lives and feeds, to investigate the effect of experimental heat stress on their symbioses with Symbiodinium. Bleaching has not been studied in nudibranchs. Bayerxenia sp. belongs to the alcyonacea family Xeniidae, members of which are known to be heat sensitive, but the genus has never been subject to heat stress experiments or bleaching observations. While qPCR did not reveal any changes to the symbiont community composition, the two host species responded differently to increased temperature. There were changes in the relative proportion of tissue types in Bayerxenia sp., but these were not attributable to the temperature treatment. Bayerxenia sp. exhibited no changes in cellular structure (apoptosis or cell necrosis), or symbiont functioning, cell size, density, or cladal community structure. On the other hand, the host, P. lizardensis, experienced tissue loss and symbiont densities decreased significantly with the majority of the remaining symbiont cells significantly degenerated after the heat stress. This decrease did not influence symbiont community composition, symbiont cell size, or photosynthetic efficiency. While the bleaching process in nudibranchs was demonstrated for the first time, the physiological and molecular pathways leading to this response still require attention. 相似文献
57.
Carina Cesar Bryan E. Shepherd Cathy A. Jenkins Massimo Ghidinelli Jose Luis Castro Valdiléa Gon?alves Veloso Claudia P. Cortes Denis Padgett Brenda Crabtree-Ramirez Eduardo Gotuzzo Valeria Fink Adriana Duran Omar Sued Catherine C. McGowan Pedro Cahn for The Caribbean Central South America Network for HIV Epidemiology 《PloS one》2014,9(9)
Background
Access to highly active antiretroviral therapy (HAART) is expanding in Latin America. Many patients require second and third line therapy due to toxicity, tolerability, failure, or a combination of factors. The need for third line HAART, essential for program planning, is not known.Methods
Antiretroviral-naïve patients ≥18 years who started first HAART after January 1, 2000 in Caribbean, Central and South America Network (CCASAnet) sites in Argentina, Brazil, Honduras, Mexico, and Peru were included. Clinical trials participants were excluded. Third line HAART was defined as use of darunavir, tipranavir, etravirine, enfuvirtide, maraviroc or raltegravir. Need for third line HAART was defined as virologic failure while on second line HAART.Results
Of 5853 HAART initiators followed for a median of 3.5 years, 310 (5.3%) failed a second line regimen and 44 (0.8%) received a third line regimen. Cumulative incidence of failing a 2nd or starting a 3rd line regimen was 2.7% and 6.0% three and five years after HAART initiation, respectively. Predictors at HAART initiation for failing a second or starting a third line included female sex (hazard ratio [HR] = 1.54, 95% confidence interval [CI] 1.18–2.00, p = 0.001), younger age (HR = 2.76 for 20 vs. 40 years, 95% CI 1.86–4.10, p<0.001), and prior AIDS (HR = 2.17, 95% CI 1.62–2.90, p<0.001).Conclusions
Third line regimens may be needed for at least 6% of patients in Latin America within 5 years of starting HAART, a substantial proportion given the large numbers of patients on HAART in the region. Improved accessibility to third line regimens is warranted. 相似文献58.
59.
Sten H. Vermund Meridith Blevins Troy D. Moon Eurico José Linda Moiane José A. Tique Mohsin Sidat Philip J. Ciampa Bryan E. Shepherd Lara M. E. Vaz 《PloS one》2014,9(10)
Introduction
Residents of Zambézia Province, Mozambique live from rural subsistence farming and fishing. The 2009 provincial HIV prevalence for adults 15–49 years was 12.6%, higher among women (15.3%) than men (8.9%). We reviewed clinical data to assess outcomes for HIV-infected children on combination antiretroviral therapy (cART) in a highly resource-limited setting.Methods
We studied rates of 2-year mortality and loss to follow-up (LTFU) for children <15 years of age initiating cART between June 2006–July 2011 in 10 rural districts. National guidelines define LTFU as >60 days following last-scheduled medication pickup. Kaplan-Meier estimates to compute mortality assumed non-informative censoring. Cumulative LTFU incidence calculations treated death as a competing risk.Results
Of 753 children, 29.0% (95% CI: 24.5, 33.2) were confirmed dead by 2 years and 39.0% (95% CI: 34.8, 42.9) were LTFU with unknown clinical outcomes. The cohort mortality rate was 8.4% (95% CI: 6.3, 10.4) after 90 days on cART and 19.2% (95% CI: 16.0, 22.3) after 365 days. Higher hemoglobin at cART initiation was associated with being alive and on cART at 2 years (alive: 9.3 g/dL vs. dead or LTFU: 8.3–8.4 g/dL, p<0.01). Cotrimoxazole use within 90 days of ART initiation was associated with improved 2-year outcomes Treatment was initiated late (WHO stage III/IV) among 48% of the children with WHO stage recorded in their records. Marked heterogeneity in outcomes by district was noted (p<0.001).Conclusions
We found poor clinical and programmatic outcomes among children taking cART in rural Mozambique. Expanded testing, early infant diagnosis, counseling/support services, case finding, and outreach are insufficiently implemented. Our quality improvement efforts seek to better link pregnancy and HIV services, expand coverage and timeliness of infant diagnosis and treatment, and increase follow-up and adherence. 相似文献60.
Benoit J. Arsenault Philip Barter David A. DeMicco Weihang Bao Gregory M. Preston John C. LaRosa Scott M. Grundy Prakash Deedwania Heiner Greten Nanette K. Wenger James Shepherd David D. Waters John J. P. Kastelein the Treating to New Targets Investigators 《PloS one》2014,9(12)
Several plasma non-lipid biomarkers have been shown to predict major cardiovascular events (MCVEs) in population studies. Our objective was to investigate the relationship between lipid and non-lipid biomarkers levels achieved during statin therapy and the incidence of MCVEs in patients with stable coronary heart disease (CHD). We conducted a substudy of the TNT (Treating to New Targets) study, which was a randomized trial that compared the efficacy of high (80 mg) versus low (10 mg) dose atorvastatin for the secondary prevention of CHD. Fasting plasma levels of standard lipids and of 18 non-lipid biomarkers were obtained after an 8-week run-in period on atorvastatin 10 mg in 157 patients who experienced MCVEs during the 4.9 years of study follow-up and in 1349 controls. MCVE was defined as CHD death, nonfatal, non-procedure-related myocardial infarction, resuscitated cardiac arrest, and fatal or nonfatal stroke. After adjusting for age, sex and treatment arm, plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, high-sensitivity C-reactive protein (hsCRP), insulin, neopterin, N-terminal pro-brain natriuretic peptide (BNP), lipoprotein(a) [Lp(a)], and the soluble receptor for advanced glycation end products (sRAGE) were predictive of recurrent MCVEs (P≤0.02 for each doubling of plasma concentration). However, no significant association was observed between the risk of recurrent MCVEs and plasma levels of low-density lipoprotein cholesterol, adiponectin, cystatin C, lipoprotein-associated phospholipase A2, monocyte chemotactic protein-1, matrix metalloproteinase-9, myeloperoxidase, osteopontin, soluble CD40 ligand, soluble intercellular adhesion molecule-1, or soluble vascular cell adhesion molecule-1. After further adjustment for diabetes, hypertension, smoking, and BMI, the relationship between hsCRP, insulin and MCVE were no longer significant, while the relationship between Lp(a), neopterin, NT-proBNP and sRAGE and MCVE remained statistically significant. In conclusion, in patients with CHD treated with atorvastatin, plasma levels of Lp(a), neopterin, NT-proBNP, and sRAGE are associated with the risk of recurrent MCVEs.